Loading stock data…
SNSE
$26.02+0.16 (+0.62%)
Pre-Market$26.02+0.00 (+0.00%)· Last close May 6
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sensei Biotherapeutics, Inc. in the Healthcare sector is trading at $26.02. The stock is currently 29% below its 52-week high of $36.76, remaining 73.6% above its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why SNSE maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$26.02
Potential Upside
5%
Whystock Fair Value$27.32
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selec...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$42.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-113.41%
Volume
Today's trading volume
22,467
Recent News
Sensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street Analysts
Sensei Biotherapeutics Inc. (NASDAQ:SNSE) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 30, Sensei Biotherapeutics shifted its focus following the acquisition of Faeth Therapeutics and a concurrent $200 million private placement. The company’s lead program is now PIKTOR, an all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. This new […]
Sensei to ditch its lead candidate and cut workforce amidst strategic review
The Boston-based biotech is axing Phase II plans for its only clinical-stage asset, in a bid to maximise shareholder value.